Építés alatt – nem éles oldal
Belépés
Résztvevőt keres itt: KínaFázis nélkül

Efficacy of Thermal Ablation Combined With Antithyroid Drugs in the Treatment of Primary Hyperthyroidism

A legfontosabb adatok

Ki végzi
Chinese PLA General Hospital
Hol
Beijing (Kína)A helyszín megnézése
Azonosító
Állapot
Toboroz
Résztvevők
454 fő, tervezett
Kezdés
2025. febr. 13.
Várható befejezés
2029. dec. 1.
A vizsgálat típusa
Megfigyeléses
A vizsgált kezelések
  • thermal ablation combined with antithyroid drug therapy
A regiszteradat frissítve
2026. április 29.

Ki vehet részt

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

The trial is looking for people with primary hyperthyroidism (an overactive thyroid) who will have thermal ablation together with antithyroid drugs. Thermal ablation destroys overactive thyroid tissue using heat.

Életkor
Up to 80 Years
Nem
All sexes
A betegség stádiuma
Primary hyperthyroidism, mild, moderate or severe. Basal metabolic rate must be within ±20% of normal, and resting heart rate controlled at ≤90 beats/min. People with moderate-to-severe Graves' eye disease (Graves' ophthalmopathy) can join. A safe needle path to the thyroid is needed.
Korábbi kezelés
People can join if antithyroid drugs did not work well enough or caused severe side effects. They can also join if radioactive iodine did not work or cannot be used for them, or if they decline surgery.

A részvétel fő kizáró okai

  • Severe blood clotting problems
  • Severe heart, liver, kidney or other major organ problems
  • Thyroid mostly behind the breastbone, or severe windpipe squeezing needing urgent relief
  • Severe bulging eyes that may get worse after the procedure, or one vocal cord not working
  • Women in the first or third trimester of pregnancy, breastfeeding, or planning pregnancy soon

A regiszter feltételei, szó szerint

Mind a 13 feltétel megnézéseKevesebb

Ki vehet részt

  • Patients diagnosed with primary hyperthyroidism based on clinical manifestations and laboratory findings
  • Patients whose basal metabolic rate (BMR) remains within ±20% of the normal reference range, and whose resting heart rate is controlled at ≤90 beats/min
  • Patients with inadequate response to standard antithyroid drug (ATD) therapy, those experiencing severe adverse reactions to ATDs, those unsuitable for or unresponsive to radioactive iodine (RAI) therapy, or those who decline conventional surgical resection and wish to undergo ablation combined with medication to shorten the treatment course and achieve rapid improvement of hyperthyroid symptoms, including patients with mild, moderate, or severe disease
  • Patients with concomitant moderate-to-severe Graves' ophthalmopathy (GO)
  • Patients with a safe needle trajectory for ablation access
  • Patients who are able to understand the purpose of the study, voluntarily participate, and provide written informed consent

Ki nem vehet részt

  • Poor general condition, such as concomitant severe cardiac, hepatic, renal, or other major organ dysfunction
  • Patients with malignant exophthalmos in whom the condition may worsen post-procedure
  • Severe coagulopathy
  • Substernal goiter or a thyroid gland largely located in the retrosternal space (relative contraindication; staged treatment may be considered)
  • Patients with significant tracheal compression requiring urgent decompression
  • Unilateral vocal cord dysfunction confirmed by laryngoscopy
  • Women in the first or third trimester of pregnancy, lactating women, or those planning pregnancy in the near future

Helyszínek itt: Kína

  • Chinese PLA General HospitalBeijing, KínaContact: Zeyu Yang, PostgraduateRésztvevőt keres

A vizsgálatról

Mit akar kideríteni a vizsgálat

Hyperthyroidism is a clinical syndrome caused by excessive production of thyroid hormones, leading to accelerated metabolism and increased excitability of multiple organ systems. Patients commonly present with polyphagia, weight loss, palpitations, and sweating. Primary hyperthyroidism is a common endocrine disorder traditionally treated with anti-thyroid drugs (ATD), radioactive iodine (¹³¹I), or surgery.

A teljes eredeti leírásKevesebb

While ATD can rapidly inhibit thyroid hormone synthesis and control symptoms, long-term use carries risks of liver damage and bone marrow suppression. Radioactive iodine involves risks of recurrence or permanent hypothyroidism, and thyroidectomy-though effective-is associated with significant trauma, potential complications, and cervical scarring. Given the limitations of these monotherapies, a combined approach leveraging thermal ablation as an adjunct to antithyroid drug therapy has emerged as a promising strategy for both rapid symptom control and long-term management.

With advances in minimally invasive techniques, thermal ablation combined with pharmacotherapy offers a balanced solution. Thermal ablation-including microwave and radiofrequency ablation-provides high precision, minimal invasiveness, and rapid recovery by directly destroying hyperfunctioning thyroid tissue under ultrasound guidance. When paired with a tailored antithyroid drug regimen, this approach not only secures immediate stabilization of thyroid function but also reduces the required drug dosage and duration, thereby mitigating drug-related adverse effects. This combined strategy maintains the cosmetic and cost-effective advantages of ablation while addressing the need for sustained endocrine control.

Studies have demonstrated that thermal ablation combined with antithyroid drugs effectively normalizes T3 and T4 levels, alleviates hypermetabolic symptoms such as palpitations and sweating, and significantly improves quality of life with a low complication rate. This integrated model is suitable for initial treatment, recurrent or refractory cases, and is particularly advantageous for patients with reduced cardiopulmonary reserve or advanced age.

However, current evidence is largely derived from single-center studies, and high-quality multicenter data are needed to validate this combined strategy. This study aims to prospectively collect baseline data from patients undergoing thermal ablation in conjunction with antithyroid drug therapy across multiple centers. The objectives are to evaluate the efficacy and safety of this combined modality, explore the factors influencing the prognosis of ablation in a medicated context, optimize postoperative medication adjustment protocols, and provide high-quality evidence to guide the standardization and clinical dissemination of this synergistic approach.

A vizsgálat csoportja

  • thyroid thermal ablation combined with antithyroid drug therapy group

    The hyperthyroidism thermal ablation combined with antithyroid drug therapy group refers to the cohort of patients with hyperthyroidism who undergo thermal ablation therapy-such as radiofrequency ablation or microwave ablation-in conjunction with antithyroid drug treatment. Patients enrolled in this group must meet clearly defined inclusion criteria and have indications for thermal ablation adjunctive to pharmacotherapy.

    Kezelés: thermal ablation combined with antithyroid drug therapy

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Multicenter Study on the Efficacy of Thermal Ablation Combined With Antithyroid Drugs in the Treatment of Primary Hyperthyroidism
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
A regiszteradat frissítve
2026. április 29.